Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07644039 · ClinicalTrials.gov registry record · Phase 1
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
A Phase 1 study, sponsored by PharmaMar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT07644039 is a Phase 1 study that is actively recruiting participants, run by PharmaMar. The registered enrollment target is 119 participants.
The verdict
NCT07644039, a Phase 1 study, is actively recruiting participants, sponsored by PharmaMar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator's assessment in participants in other cohorts.
Interventions
- DRUG Pembrolizumab
- DRUG PM54
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2029-04-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07644039
The ClinicalTrials.gov registry entry for NCT07644039 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07644039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07644039 about?
NCT07644039 is a clinical study titled "Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies". The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investig...
What is the current status of trial NCT07644039?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2026-05-21. Estimated completion is 2029-04-02.
What interventions are being tested in trial NCT07644039?
The interventions under investigation include: Pembrolizumab (DRUG), PM54 (DRUG).
Who is sponsoring clinical trial NCT07644039?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.